Published in Res Commun Chem Pathol Pharmacol on March 01, 1979
Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man. Br J Clin Pharmacol (1982) 0.93
Stereoselective ring oxidation of propranolol in man. Br J Clin Pharmacol (1984) 0.82
Changes in neurotransmitter sensitivity in the mouse neocortical slice following propranolol and theophylline administration. Br J Pharmacol (1991) 0.76
The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers. Br J Pharmacol (1991) 0.76
The predictable relationship between plasma levels and dose during chronic propranolol therapy. Clin Pharmacol Ther (1978) 1.51
Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. Clin Pharmacol Ther (1986) 1.31
Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol (1999) 1.25
GLC determination of propranolol, other beta-blocking drugs, and metabolites in biological fluids and tissues. J Pharm Sci (1974) 1.22
Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol (2001) 1.21
Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem Pharmacol (1998) 1.18
Propranolol metabolism in man and dog: mass spectrometric identification of six new metabolites. J Pharmacol Exp Ther (1972) 1.17
Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodium-dependent glucose transporter SGLT1. J Pharmacol Exp Ther (2000) 1.14
Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Drug Metab Dispos (1996) 1.11
Extensive binding of the bioflavonoid quercetin to human plasma proteins. J Pharm Pharmacol (1998) 1.10
Naphthoxylactic acid after single and long-term doses of propranolol. Clin Pharmacol Ther (1979) 1.10
Transport and metabolism of the tea flavonoid (-)-epicatechin by the human intestinal cell line Caco-2. Pharm Res (2001) 1.06
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther (1989) 1.05
Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos (1998) 1.02
Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther (2000) 1.01
Stereoselective binding of propranolol to human plasma, alpha 1-acid glycoprotein, and albumin. Clin Pharmacol Ther (1983) 1.01
4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther (1980) 1.00
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation. Pharm Res (2001) 1.00
Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. Res Commun Chem Pathol Pharmacol (1993) 1.00
Methylation protects dietary flavonoids from rapid hepatic metabolism. Xenobiotica (2006) 0.99
Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol (2002) 0.98
Food-induced increase in propranolol bioavailability--relationship to protein and effects on metabolites. Clin Pharmacol Ther (1981) 0.98
Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica (1999) 0.97
Fate of the flavonoid quercetin in human cell lines: chemical instability and metabolism. J Pharm Pharmacol (1999) 0.95
Acetylation of spermidine and spermine by rat liver and kidney chromatin. Arch Biochem Biophys (1977) 0.95
Stereoselective sulphate conjugation of fenoterol by human phenolsulphotransferases. Xenobiotica (1997) 0.94
Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity. Br J Clin Pharmacol (1993) 0.93
Taxol metabolism and disposition in cancer patients. Drug Metab Dispos (1995) 0.93
Quercetin glucosides are completely hydrolyzed in ileostomy patients before absorption. J Nutr (2000) 0.93
Induction of UDP-glucuronosyltransferase by the flavonoids chrysin and quercetin in Caco-2 cells. Pharm Res (2000) 0.93
Exercise-induced increments in plasma levels of propranolol and noradrenaline. Br J Clin Pharmacol (1983) 0.92
Quantitative account of propranolol metabolism in urine of normal man. Drug Metab Dispos (1985) 0.92
Identification of the unusual polyamines 3,3'-diaminodipropylamine and N,N'-bis(3-aminoproply)-1,3-propanediamine in the white shrimp Penaeus setiferus. Biochem Biophys Res Commun (1977) 0.91
Quercetin and resveratrol potently reduce estrogen sulfotransferase activity in normal human mammary epithelial cells. J Steroid Biochem Mol Biol (2000) 0.90
Stereoselective clearance and distribution of intravenous propranolol. Clin Pharmacol Ther (1984) 0.90
Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women. Br J Clin Pharmacol (1996) 0.90
S-adenosyl-L-methionine: transcellular transport and uptake by Caco-2 cells and hepatocytes. J Pharm Pharmacol (2005) 0.89
Stereoselective sulphate conjugation of salbutamol by human lung and bronchial epithelial cells. Br J Clin Pharmacol (1996) 0.89
Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother Pharmacol (1995) 0.88
Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin Pharmacol Ther (1985) 0.88
Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab Dispos (2000) 0.88
Hep G2 cell line as a human model for sulphate conjugation of drugs. Xenobiotica (1992) 0.87
Transport of genistein-7-glucoside by human intestinal CACO-2 cells: potential role for MRP2. Res Commun Mol Pathol Pharmacol (1999) 0.87
Carbon dioxide is the major metabolite of quercetin in humans. J Nutr (2001) 0.87
Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. J Pharmacol Exp Ther (1983) 0.86
Presystemic and systemic glucuronidation of propranolol. Clin Pharmacol Ther (1979) 0.86
Bioactivation of the cooked food mutagen N-hydroxy-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by estrogen sulfotransferase in cultured human mammary epithelial cells. Carcinogenesis (1998) 0.86
Isopropylamine, a biologically active deamination product of propranolol in dogs: identification of deuterated and unlabeled isopropylamine by gas chromatography-mass spectrometry. J Pharmacol Exp Ther (1972) 0.85
Isolation from urine of 4'-hydroxypropranolol sulfate, a major new propranolol metabolite, by ion-pair extraction. J Chromatogr (1984) 0.85
Stimulation-induced release of propranolol and norepinephrine from adrenergic neurons. J Pharmacol Exp Ther (1979) 0.84
Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br J Clin Pharmacol (1986) 0.84
New ring-hydroxylated metabolites of propranolol: species differences and stereospecific 7-hydroxylation. Drug Metab Dispos (1982) 0.84
Simultaneous determination of propranolol and 4-hydroxypropranolol in plasma by mass fragmentography. J Chromatogr (1975) 0.84
Propranolol effects on membrane repolarization time in isolated canine Purkinje fibers: threshold tissue content and the influence of exposure time. J Pharmacol Exp Ther (1980) 0.84
Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol. Cancer Chemother Pharmacol (1995) 0.83
Association of in vivo and in vitro propranolol levels in canine Purkinje fibers with antiarrhythmic effects. J Pharmacol Exp Ther (1977) 0.83
Combined effects of propranolol and ethanol on human psychomotor performance. Toxicol Appl Pharmacol (1983) 0.83
Quantitative metabolic fate of propranolol in the dog, rat, and hamster using radiotracer, high performance liquid chromatography, and gas chromatography-mass spectrometry techniques. Drug Metab Dispos (1983) 0.83
Identification of major sulfate conjugates in the metabolism of propranolol in dog and man. Drug Metab Dispos (1983) 0.83
Adrenergic nerve stimulation-induced release of propranolol from the perfused hindlimb and spleen of the dog and associated changes in postjunctional response. J Pharmacol Exp Ther (1983) 0.83
Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers. J Med Chem (1981) 0.82
Separation of the enantiomers of intact sulfate conjugates of adrenergic drugs by high-performance liquid chromatography after chiral derivatization. J Chromatogr (1985) 0.82
Cytotoxic effects of the dietary flavones chrysin and apigenin in a normal trout liver cell line. Chem Biol Interact (2007) 0.82
Stereoselective sulphate conjugation of racemic terbutaline by human liver cytosol. Br J Clin Pharmacol (1990) 0.82
Influence of food on the intravenous and oral dose kinetics of propranolol in the dog. J Pharmacokinet Biopharm (1985) 0.82
Stereochemical composition of propranolol metabolites in the dog using stable isotope-labeled pseudoracemates. Drug Metab Dispos (1984) 0.82
Stereoselective ring oxidation of propranolol in man. Br J Clin Pharmacol (1984) 0.82